P426 Association Between vedolizumab therapy outcome and Pre-treatment DUBLIN Score & CRP-Albumin Ratio in Ulcerative Colitis
McCormick, E.(1);Singh, P.(1);Kevans, D.(1);
(1)St James's Hospital, Gastroenterology, Dublin, Ireland;
The DUBLIN score is a measure of ulcerative colitis (UC) inflammatory burden and is associated with clinical outcomes. A high CRP/albumin ratio (CAR) is associated with disease severity in IBD. The aim of our study was to evaluate if there was an association between vedolizumab therapy outcome and pre-treatment DUBLIN score and CAR in UC.
35 patients with UC initiating vedolizumab with available pre-treatment DUBLIN score and CAR data were identified. Baseline characteristics, biochemistry and endoscopic findings were defined by retrospective review. A previously validated DUBLIN score threshold of ≥3 and CAR threshold >0.6 were utilised to categorise patients with high inflammatory burden. Clinical response at 3-months and corticosteroid-free remission at 6-months were recorded. The association between 3-month clinical response and 6-month remission rates & pre-treatment DUBLIN score and CAR ratio were evaluated. P values <0.05 were considered significant.
Baseline characteristics of the study cohort: age [median, range] 53 [19 -87] years; 60% male; disease duration [median, range] 11 [2-41] years. A pre-treatment DUBLIN score ≥3 and CAR >0.6 were observed in 65% and 51% of patients respectively. 3-month clinical response and 6-month corticosteroid-free remission rates were observed in 79% and 67% of the cohort respectively. There was no significant difference between rates of 3-month clinical response and 6-month corticosteroid-free remission comparing high and low pretreatment DUBLIN score and CAR groups, p=0.59 and p=0.16 respectively.
Vedolizumab was an effective therapy in patients with a significant inflammatory burden assessed by DUBLIN score and CAR. Pre-treatment DUBLIN score and CAR were not associated with therapy outcome.